Eli Lilly's stock price has over-corrected following a downgrade in its outlook following the adjustment for acquisition ...

Eli Lilly (NYSE:LLY) announced a significant global licensing and research collaboration with Juvena Therapeutics to explore AI-driven drug candidates for muscle health. This innovative move ...

Eli Lilly has a very high P/E ratio of 62, which is more than double the average for the sector. Based on this, the shares look expensive but it is worth considering despite the premium.

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Joe Gebbia, a confidant of the technology billionaire and a Tesla director, is also a leader of the federal cost-cutting team ...

Benzinga Bulls And Bears: Eli Lilly, Okto, McDonalds — And Israel-Iran Conflict Sparks Oil Surge by Benzinga Senior Editor Follow Add Comment ...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

Stocks rose Monday, with oil prices declining, following a restrained response by Iran to U.S. attacks over the weekend.

U.S. stocks slumped under the weight of a jump for the price of oil. The S&P 500 fell 0.8% Tuesday following signals that ...

The timing is also interesting. GLP-1s are Novo Nordisk's biggest and fastest-growing revenue stream, and competition is heating up. Eli Lilly's Zepbound is gaining traction, compounded access is ...

US stocks are down after Trump had harsh words for Iran, saying he would not target the country's leader "for now." Fed's ...